Br J Cancer

• 

  Publication Venue For

  • Manassantin A inhibits tumour growth under hypoxia through the activation of chaperone-mediated autophagy by modulating Hsp90 activity..  128:1491-1502. 2023
  • Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study..  128:137-147. 2023
  • Racial differences in the association of body mass index and ovarian cancer risk in the OCWAA Consortium..  127:1983-1990. 2022
  • Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients..  126:718-725. 2022
  • PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer..  126:778-790. 2022
  • The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients..  126:791-796. 2022
  • Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients..  126:265-274. 2022
  • Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients..  126:162. 2022
  • Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast..  125:1443-1449. 2021
  • Communication around palliative care principles and advance care planning between oncologists, children with advancing cancer and families..  125:1089-1099. 2021
  • Searching for causal relationships of glioma: a phenome-wide Mendelian randomisation study..  124:447-454. 2021
  • Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank..  123:1356-1359. 2020
  • Endpoint surrogacy in oncology Phase 3 randomised controlled trials..  123:333-334. 2020
  • Ductal carcinoma in situ: to treat or not to treat, that is the question..  121:285-292. 2019
  • Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer..  119:1451-1455. 2018
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma..  119:663-669. 2018
  • A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features..  119:508-516. 2018
  • Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''..  119:260-262. 2018
  • Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)..  118:1434-1441. 2018
  • Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis..  118:1337-1348. 2018
  • Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study..  118:1123-1129. 2018
  • Influence of obesity-related risk factors in the aetiology of glioma..  118:1020-1027. 2018
  • Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)..  118:648-653. 2018
  • Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations..  117:1685-1688. 2017
  • Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up..  117:1723-1731. 2017
  • History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report..  117:1063-1069. 2017
  • Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study..  117:290-299. 2017
  • Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium..  116:1223-1228. 2017
  • Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci..  116:524-535. 2017
  • Dairy, calcium, vitamin D and ovarian cancer risk in African-American women..  115:1122-1130. 2016
  • Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium..  115:95-101. 2016
  • Analgesic medication use and risk of epithelial ovarian cancer in African American women..  114:819-825. 2016
  • A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer..  113:1421-1426. 2015
  • Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium..  113:817-826. 2015
  • Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer..  113:453-459. 2015
  • Best supportive care in clinical trials: review of the inconsistency in control arm design..  113:6-11. 2015
  • Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study..  112:825-831. 2015
  • Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial..  110:2427-2433. 2014
  • Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer..  107:1783-1790. 2012
  • Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients..  107:1481-1487. 2012
  • Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours..  107:1399-1408. 2012
  • Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer..  107:482-490. 2012
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification..  106:916-922. 2012
  • The DNA damage response in viral-induced cellular transformation..  106:429-435. 2012
  • End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age..  105:28-37. 2011
  • Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer..  105:9-12. 2011
  • Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma..  105:112-117. 2011
  • Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration..  104:1575-1586. 2011
  • Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumour)..  104:1452-1458. 2011
  • Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study..  104:413-418. 2011
  • The need for a re-evaluation of best supportive care studies reported to date..  104:390-391. 2011
  • Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor..  103:1554-1561. 2010
  • Guidelines for the welfare and use of animals in cancer research..  102:1555-1577. 2010
  • Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes..  102:301-315. 2010
  • Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine..  102:144-150. 2010
  • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody..  102:124-133. 2010
  • Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families..  101:2043-2047. 2009
  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study..  101:1986-1994. 2009
  • Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis..  101:1461-1468. 2009
  • MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition..  101:269-277. 2009
  • Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium..  100:412-420. 2009
  • A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer..  99:722-726. 2008
  • In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs..  99:294-304. 2008
  • A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. 2018